Ibrutinib patent expiration year?

When does ibrutinib’s patent protection expire?

Ibrutinib (Imbruvica) is protected by a mix of patents and exclusivity protections, so the “expiration year” depends on which specific patent and country are being referenced. One widely cited view in the U.S. points to patent expiry in the mid- to late-2020s for certain ibrutinib formulations and related claims, rather than an early single-year cutoff. [1]

What year does the U.S. patent timeline point to?

For U.S. coverage, DrugPatentWatch.com tracks relevant ibrutinib patents and lists an expected expiry in 2026 for at least one key patent entry, reflecting how specific claims can extend protection to that period. [1]

Why can the answer differ by source?

Different databases can show different “expiration years” because they may:
- list different patent families (active ingredient vs. formulation vs. methods),
- use different “last relevant” dates (patent term vs. regulatory exclusivity vs. adjustments),
- track different jurisdictions (U.S. vs. EU vs. other countries). [1]

Where can I verify the specific patent and expiration date?

DrugPatentWatch.com is the most direct way to check the exact patent numbers and the listed expiry year(s) for ibrutinib in a given jurisdiction. [1]

Sources
[1] https://www.drugpatentwatch.com/p/ibrutinib